Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone650-249-9090
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$257.65 million
Profitability
Miscellaneous
Employees975
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Natera (NASDAQ:NTRA) Frequently Asked Questions
What is Natera's stock symbol?
Natera trades on the NASDAQ under the ticker symbol "NTRA."
How were Natera's earnings last quarter?
Natera Inc (NASDAQ:NTRA) posted its quarterly earnings results on Wednesday, August, 7th. The medical research company reported ($0.48) EPS for the quarter, beating the Zacks' consensus estimate of ($0.57) by $0.09. The medical research company had revenue of $74.36 million for the quarter, compared to analysts' expectations of $66.77 million. Natera had a negative net margin of 46.78% and a negative return on equity of 273.92%. The business's revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.62) earnings per share. View Natera's Earnings History.
When is Natera's next earnings date?
What guidance has Natera issued on next quarter's earnings?
Natera issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $275-305 million, compared to the consensus revenue estimate of $288.5 million.
What price target have analysts set for NTRA?
6 brokers have issued twelve-month target prices for Natera's shares. Their forecasts range from $26.00 to $41.00. On average, they anticipate Natera's share price to reach $34.00 in the next year. This suggests a possible upside of 0.8% from the stock's current price. View Analyst Price Targets for Natera.
What is the consensus analysts' recommendation for Natera?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.
What are Wall Street analysts saying about Natera stock?
Here are some recent quotes from research analysts about Natera stock:
- 1. Canaccord Genuity analysts commented, "We recently had the privilege of hosting Natera CEO Steve Chapman and CFO a well-attended fireside chat at the 39th in Boston. We continue to view NTRA as an undervalued cancer company trading at the multiple of an NIPT company. NTRA remains one of our favorite stocks and is one of our top picks for 2019. We reiterate our BUY rating and $38 PT. Signatera may be a game-changer in recurrence monitoring and MRD." (9/11/2019)
- 2. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (8/9/2019)
Has Natera been receiving favorable news coverage?
Media coverage about NTRA stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Natera earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Natera.
Are investors shorting Natera?
Natera saw a decline in short interest during the month of August. As of August 15th, there was short interest totalling 3,093,800 shares, a decline of 27.5% from the July 15th total of 4,267,100 shares. Based on an average daily volume of 717,000 shares, the short-interest ratio is currently 4.3 days. Approximately 6.6% of the company's stock are sold short. View Natera's Current Options Chain.
Who are some of Natera's key competitors?
Some companies that are related to Natera include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), InVitae (NVTA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Personalis (PSNL), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN) and PotNetwork (POTN).
What other stocks do shareholders of Natera own?
Who are Natera's key executives?
Natera's management team includes the folowing people:
- Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)
- Mr. Steve Chapman, CEO, Pres & Director (Age 40)
- Mr. Michael Brophy, Chief Financial Officer (Age 39)
- Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)
- Mr. Robert A. Schueren, Chief Operating Officer (Age 57)
When did Natera IPO?
(NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
Who are Natera's major shareholders?
Natera's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.05%), BlackRock Inc. (6.90%), Jennison Associates LLC (6.37%), Jennison Associates LLC (6.37%), Orbimed Advisors LLC (4.60%) and Invesco Ltd. (2.93%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.
Which major investors are selling Natera stock?
NTRA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, D. E. Shaw & Co. Inc., Price T Rowe Associates Inc. MD, A.R.T. Advisors LLC, Point72 Asset Management L.P., Morgan Stanley, Strs Ohio and BNP Paribas Arbitrage SA. Company insiders that have sold Natera company stock in the last year include Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera.
Which major investors are buying Natera stock?
NTRA stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, BlackRock Inc., Invesco Ltd., Wells Fargo & Company MN, Nuveen Asset Management LLC, Jennison Associates LLC, Jennison Associates LLC and Vanguard Group Inc.. View Insider Buying and Selling for Natera.
How do I buy shares of Natera?
Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Natera's stock price today?
One share of NTRA stock can currently be purchased for approximately $33.72.
How big of a company is Natera?
Natera has a market capitalization of $2.36 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe.View Additional Information About Natera.
What is Natera's official website?
How can I contact Natera?
Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]
MarketBeat Community Rating for Natera (NASDAQ NTRA)
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
